Biologic therapy and its effect on skeletal development in children with chronic inflammation

Expert Review of Endocrinology and Metabolism

Volumn 5, Issue 5, 2010, Pages 733-740

  Malik, Salma ^a   Ahmed, S Faisal ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

anti TNF therapy; biologics; chronic inflammation; growth failure; inflammatory bowel disease; infliximab; skeletal development; TNF blockers

Indexed keywords

ADALIMUMAB; ETANERCEPT; FOLLITROPIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; INFLIXIMAB; LUTEINIZING HORMONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; BONE DEVELOPMENT; CHILD; CHRONIC INFLAMMATION; CROHN DISEASE; GROWTH DISORDER; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; NUTRITION; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

EID: 77956822054     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.44     Document Type: Review

References (65)

1. Karlberg J, Jalil F, Lam B, Low L, Yeung CY. Linear growth retardation in relation to the three phases of growth. Eur. J. Clin. Nutr. 48(Suppl. 1), S25-S43 (1994).
2. Goldenberg N, Barkan A. Factors regulating growth hormone secretion in humans. Endocrinol. Metab. Clin. North Am. 36(1), 37-55 (2007).
3. Bougneres P, Goffin V. The growth hormone receptor in growth. Endocrinol. Metab. Clin. North Am. 36(1), 1-16 (2007).
4. Isaksson OG, Jansson JO, Gause IA. Growth hormone stimulates longitudinal bone growth directly. Science 216(4551), 1237-1239 (1982).
5. Green H, Morikawa M, Nixon T. A dual effector theory of growth-hormone action. Differentiation 29(3), 195-198 (1985).
6. Zezulak KM , Green H. The generation of insulin-like growth factor-1 - sensitive cells by growth hormone action. Science 233(4763), 551-553 (1986).
7. Perry RJ, Farquharson C, Ahmed SF. The role of sex steroids in controlling pubertal growth. Clin. Endocrinol. (Oxf.) 68(1), 4-15 (2008).
8. Briard N, Guillaume V, Frachebois C et al. Endotoxin injection increases growth hormone and somatostatin secretion in sheep. Endocrinology 139(6), 2662-2669 (1998). (Pubitemid 28512372)
9. Daniel JA, Elsasser TH, Martinez A, Steele B, Whitlock BK, Sartin JL. Interleukin-1b and tumor necrosis factor-a mediation of endotoxin action on growth hormone. Am. J. Physiol. Endocrinol. Metab. 289(4), E650-E657 (2005).
10. Gong FY, Deng JY, Shi YF. Stimulatory effect of interleukin-1b on growth hormone gene expression and growth hormone release from rat GH3 cells. Neuroendocrinology 81(4), 217-228 (2005).
11. Soto L, Martin AI, Millan S, Vara E, Lopez-Calderon A. Effects of endotoxin lipopolysaccharide administration on the somatotropic axis. J. Endocrinol. 159(2), 239-246 (1998).
12. Wada Y, Sato M, Niimi M, Tamaki M, Ishida T, Takahara J. Inhibitory effects of interleukin-1 on growth hormone secretion in conscious male rats. Endocrinology 136(9), 3936-3941 (1995).
13. Peisen JN, McDonnell KJ, Mulroney SE, Lumpkin MD. Endotoxin-induced suppression of the somatotropic axis is mediated by interleukin-1 b and corticotropin-releasing factor in the juvenile rat. Endocrinology 136(8), 3378-3390 (1995).
14. Haedo MR, Gerez J, Fuertes M et al. Regulation of pituitary function by cytokines. Horm. Res. 72(5), 266-274 (2009).
15. Martensson K, Chrysis D, Savendahl L. Interleukin-1b and TNF-a act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J. Bone Miner. Res. 19(11), 1805-1812 (2004).
16. MacRae VE, Farquharson C, Ahmed SF. The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J. Endocrinol. 189(2), 319-328 (2006).
17. MacRae VE, Wong SC, Smith W et al. Cytokine profiling and in vitro studies of murine bone growth using biological fluids from children with juvenile idiopathic arthritis. Clin. Endocrinol. (Oxf.) 67(3), 442-448 (2007).
18. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208, 207-227 (2005).
19. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol. Rev. 208, 154-168 (2005).
20. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohns disease on bone metabolism in vitro: a role for interleukin-6. J. Bone Miner. Res. 17(4), 695-702 (2002).
21. Tatsumi S, Ishii K, Amizuka N et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5(6), 464-475 (2007).
22. Tan SD, Kuijpers-Jagtman AM, Semeins CM et al. Fluid shear stress inhibits TNFa-induced osteocyte apoptosis. J. Dent. Res. 85(10), 905-909 (2006).
23. Belli DC, Seidman E, Bouthillier L et al. Chronic intermittent elemental diet improves growth failure in children with Crohns disease. Gastroenterology 94(3), 603-610 (1988).
24. Polk DB, Hattner JA, Kerner JA Jr. Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohns disease. JPEN J. Parenter. Enteral. Nutr. 16(6), 499-504 (1992).
25. Morin CL, Roulet M, Roy CC, Weber A. Continuous elemental enteral alimentation in children with Crohns disease and growth failure. Gastroenterology 79(6), 1205-1210 (1980).
26. Wong SC, MacRae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J. Pediatr. Gastroenterol. Nutr. 43(2), 144-155 (2006).
27. Zak M, Muller J, Karup PF. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis. A long-term follow-up study. Horm. Res. 52(2), 80-85 (1999).
28. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Treatment of growth failure in juvenile chronic arthritis. Horm. Res. 58(Suppl. 1), 28-32 (2002).
29. Hankard R, Munck A, Navarro J. Nutrition and growth in cystic fibrosis. Horm. Res. 58(Suppl. 1), 16-20 (2002).
30. Lilleby V, Lien G, Frey FK, Haugen M, Flato B, Forre O. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum. 52(7), 2051-2059 (2005).
31. Kotaniemi A, Savolainen A, Kroger H, Kautiainen H, Isomaki H. Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand. J. Rheumatol. 28(1), 19-26 (1999).
32. Leonard MB, Shults J, Wilson BA, Tershakovec AM, Zemel BS. Obesity during childhood and adolescence augments bone mass and bone dimensions. Am. J. Clin. Nutr. 80(2), 514-523 (2004).
33. Nilsson O, Marino R, De Luca F, Phillip M, Baron J. Endocrine regulation of the growth plate. Horm. Res. 64(4), 157-165 (2005).
34. Petit MA, Beck TJ, Shults J, Zemel BS, Foster BJ, Leonard MB. Proximal femur bone geometry is appropriately adapted to lean mass in overweight children and adolescents. Bone 36(3), 568-576 (2005).
35. Burnham JM, Shults J, Semeao E et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J. Bone Miner. Res. 19(12), 1961-1968 (2004).
36. Daci E, van Cromphaut S, Bouillon R. Mechanisms influencing bone metabolism in chronic illness. Horm. Res. 58(Suppl. 1), 44-51 (2002).
37. Cezard JP, Touati G, Alberti C, Hugot JP, Brinon C, Czernichow P. Growth in paediatric Crohns disease. Horm. Res. 58(Suppl. 1), 11-15 (2002).
38. Haworth CS, Selby PL, Webb AK et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 59(7), 613-617 (2004).
39. Aris RM, Stephens AR, Ontjes DA et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 162(5), 1674-1678 (2000).
40. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohns disease. Pediatrics 118(1), 124-129 (2006).
41. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 18(2), 165-173 (1994). (Pubitemid 24056474)
42. Buller HA. Growth in children with inflammatory bowel disease. Research and Clinical Forums 22, 139-144 (2000).
43. Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS. Growth, body composition, and nutritional status in children and adolescents with Crohns disease. J. Pediatr. Gastroenterol. Nutr. 31(1), 33-40 (2000).
44. Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm. Bowel Dis. 12(8), 797-813 (2006).
45. Pappa HM, Gordon CM, Saslowsky TM et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 118(5), 1950-1961 (2006).
46. Sylvester FA. IBD and skeletal health: children are not small adults! Inflamm. Bowel Dis. 11(11), 1020-1023 (2005).
47. Issenman RM. Bone mineral metabolism in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 5(3), 192-199 (1999).
48. Sylvester FA, Wyzga N, Hyams JS et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm. Bowel Dis. 13(1), 42-50 (2007).
49. Harpavat M, Greenspan SL, OBrien C, Chang CC, Bowen A, Keljo DJ. Altered bone mass in children at diagnosis of Crohn disease: a pilot study. J. Pediatr. Gastroenterol. Nutr. 40(3), 295-300 (2005).
50. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6(1), 75-92 (2007).
51. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin. Rheumatol. 27(1), 67-76 (2008).
52. Diamanti A, Basso MS, Gambarara M et al. Positive impact of blocking tumor necrosis factor a on the nutritional status in pediatric Crohns disease patients. Int. J. Colorectal Dis. 24(1), 19-25 (2009).
53. Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohns disease. J. Pediatr. Gastroenterol. Nutr. 42(1), 40-45 (2006).
54. Cezard JP, Nouaili N, Talbotec C et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric crohn disease. J. Pediatr. Gastroenterol. Nutr. 36(5), 632-636 (2003).
55. Borrelli O, Bascietto C, Viola F et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohns disease. Dig. Liver Dis. 36(5), 342-347 (2004).
56. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohns disease. Inflamm. Bowel Dis. 13(4), 424-430 (2007).
57. Thayu M, Leonard MB, Hyams JS et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohns disease: results of the REACH study. Clin. Gastroenterol. Hepatol. 6(12), 1378-1384 (2008).
58. Pfefferkorn M, Burke G, Griffiths A et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J. Pediatr. Gastroenterol. Nutr. 48(2), 168-174 (2009).
59. Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin. Exp. Rheumatol. 21(6), 779-784 (2003).
60. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann. Rheum. Dis. 65(8), 1044-1049 (2006).
61. Vojvodich PF, Hansen JB, Andersson U, Savendahl L, Hagelberg S. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J. Rheumatol. 34(12), 2481-2485 (2007).
62. Ryan BM, Russel MG, Schurgers L et al. Effect of antitumour necrosis factor-a therapy on bone turnover in patients with active Crohns disease: a prospective study. Aliment. Pharmacol. Ther. 20(8), 851-857 (2004).
63. Miheller P, Muzes G, Racz K et al. Changes of OPG and RANKL concentrations in Crohns disease after infliximab therapy. Inflamm. Bowel Dis. 13(11), 1379-1384 (2007).
64. Abreu MT, Geller JL, Vasiliauskas EA et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohns disease. J. Clin. Gastroenterol. 40(1), 55-63 (2006).
65. Franchimont N, Putzeys V, Collette J et al. Rapid improvement of bone metabolism after infliximab treatment in Crohns disease. Aliment. Pharmacol. Ther. 20(6), 607-614 (2004).